Literature DB >> 225026

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

P A Radice, P A Bunn, D C Ihde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 225026

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  36 in total

1.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Authors:  D Fulton; R Urtasun; P Forsyth
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

Authors:  F Kung; F A Hayes; J Krischer; D Mahoney; B Leventhal; G Brodeur; D H Berry; R Dubowy; S Toledano
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

Review 4.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

5.  Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.

Authors:  L Dabich; M K Liepman
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 6.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines.

Authors:  H Morimoto; P Principe; J P Robin; C Broquet; J M Mencia-Huerta; P Braquet; B Bonavida
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.

Authors:  J D Licht; R Mazanet; P J Loehrer; R Gonin; K H Antman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  A phase I trial of continuous infusion VP16-213 (etoposide).

Authors:  J Aisner; D A Van Echo; M Whitacre; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

Authors:  R E Taylor; T J McElwain; A Barrett; M J Peckham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.